MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in total cash, cash equivalents and investments Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) ...